Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Invitation to Attend Orexo's Capital Markets Day via Teleconference


News provided by

Orexo

12 Mar, 2020, 17:12 GMT

Share this article

Share toX

Share this article

Share toX

UPPSALA, Sweden, March 12, 2020 /PRNewswire/ -- As previously communicated, Orexo invites investors, analysts and the media to participate in the company's Capital Markets Day in Stockholm, Sweden, on March 17, at Helio GT30, Grev Turegatan 30.

Due to the ongoing COVID-19 outbreak, the company is carefully following daily recommendations from the Swedish Public Health Authority to prevent further spread of COVID-19, as the welfare of our employees and visitors is of significant importance. In parallel, Orexo has decided to introduce travel restrictions for non-critical business events and meetings, meaning that Orexo's US-based team will not be attending the Capital Markets Day in person, but will still be presenting virtually during the event taking place.

For those planning on attending the event in person, we ask you to carefully consider the Visitation Policy at the end of this press release before attending.

To increase access to our Capital Markets Day, we will also host a telephone conference from 1.30 CET, allowing those attending via phone or online to also participate in the Q&A. To participate please see below:

Telephone: SE: +46-8-505-583-65, UK: +44-33-330-09-264, US: +1-646-722-49-56

Internet: https://tv.streamfabriken.com/orexo-cmd-2020

The agenda for the day is displayed below. To register to attend in person for the event please use the following link:

https://financialhearings.com/event/12588/register/live_event

                                        

Time pm CET

                                   

Topic or activity

                 

 

Presenter                                               

                                   

1:00 - 1.30

                                   

Registration and coffee





Part 1 - Growth Strategy

                                   

1:30 - 1:45 

                     

Strategy for short- and long-term growth 

 

Nikolaj Sørensen, CEO and President                                               

                                   

1:45 - 2:00

                                   

Growing the Zubsolv® franchise

 

   

Robert DeLuca, President of Orexo US Inc                                             




Part 2 - Pharma R&D Pipeline

                                   

2:00 - 2:20 

                                   

A pipeline with significant future potential 

 

Johannes Doll, EVP and Chief Commercial Officer                                               

                                   

2:20 - 2:25

               

Q&A session


                                   

2:25 - 2:35

                                   

Break





Part 3 - Digital Therapeutics (DTx)

2:35 - 3:05 

DTx - new frontiers in patient care                                    

 

 

Dennis Urbaniak, EVP Digital Therapeutics                                               

                                   

3:05 - 3:40

                                   

GAIA - a global leader in digital therapeutics

                                   

Dr. Mario Weiss, CEO and founder of GAIA AG              

                                   

3:40 - 3:55

                                   

Q&A session


                                   

3:55 - 4:00

                                   

Concluding remarks

Nikolaj Sørensen, CEO and President                                                

                                   

4:00

                                   

Mingle and buffet


Robert Rönn, VP and Head of R&D, and Mike Sumner, Chief Medical Officer, will attend the Q&A sessions.

We will announce if there will be further changes ahead of the Capital Markets Day.

For further information, please contact:

Orexo AB (publ.)

Lena Wange, IR and Communications Manager

Tel: +46-(0)-18-780-88-00

Email: ir@orexo.com                                          






About Orexo

Orexo develops and commercializes improved pharmaceuticals and digital therapeutics, addressing unmet medical needs mainly within the growing space of addiction. Approved products are commercialized by Orexo in the US or worldwide via partners. Orexo's main market is the US for buprenorphine/naloxone products, where Orexo commercializes its lead product Zubsolv®, for the treatment of opioid use disorder. Total net sales for 2019 amounted to SEK 844.8 million and the number of employees was 128. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities are performed.

For more information about Orexo and the Capital Markets Day please visit, www.orexo.com. You can also follow Orexo on Twitter (#OrexoCMD20), @orexoabpubl, LinkedIn and YouTube.

Visiting policy Orexo Capital Markets Day

We kindly ask visitors attending Orexo's Capital Markets Day event to consider the below criteria and information carefully before attending on the day. If you fit into any of the below criteria, we kindly ask you to not attend the event in person but to join us online.

- If you have travelled to, from or via China, Hong Kong, Italy, Austria (specifically Tyrolia), Iran as well as the city of Daegu and Gyeongsang Province in South Korea for the past 14 days.

- If you have had family members or guest staying with you who have travelled to, from or via China, Hong Kong, Italy, Austria (specifically Tyrolia), Iran as well as the city of Daegu and Gyeongsang Province in South Korea for the past 14 days.

- If you are experiencing flu or cold-like symptoms, such as a fever, cough, difficulty breathing or shortness of breath. This also applies to mild symptoms.

To prevent further spread of COVID-19, we are implementing preventative measures such as avoiding any physical contact during the event. Antibacterial hand gel will also be made available at the event.

The advice to prevent respiratory tract infections is to avoid touching your face or eyes and avoiding close contact with those who have fallen ill. Wash your hands frequently with soap and warm water, before meals, food handling and after a toilet visit. Coughing and sneezing in the arm fold or a paper handkerchief will lessen the risk of contamination and further spread.

The information was submitted for publication at 5:30 pm CET, on March 12, 2020.

CONTACT:

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/orexo/r/invitation-to-attend-orexo-s-capital-markets-day-via-teleconference,c3058254

The following files are available for download:

https://mb.cision.com/Main/694/3058254/1210352.pdf

Invitation to attend Orexo´s Capital Markets Day via teleconference

Modal title

Also from this source

Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology

Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces positive in-vivo proof-of-concept data for a powder-based intranasal vaccine candidate...

Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis

Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces positive topline results from the clinical study OX640-002. The study evaluated the...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

Conference Call Announcements

Conference Call Announcements

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.